Premium
Secondary chemotherapy of advanced breast cancer
Author(s) -
Goldenberg Ira S.,
McMahan C. A.,
Escher George C.,
Volk Herbert,
Ansfield Fred J.,
Olson Kenneth B.
Publication year - 1973
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197303)31:3<660::aid-cncr2820310326>3.0.co;2-u
Subject(s) - chlorambucil , prednisone , medicine , breast cancer , oncology , chemotherapy , triiodothyronine , cancer , metastatic breast cancer , hydrocortisone , hormone , cyclophosphamide
A randomized, protocol study by the Cooperative Breast Cancer Group has demonstrated the efficacy of chlorambucil, prednisone, hydrocortisone, and triiodothyronine as secondary therapy for advanced female breast cancer. Objective regression rates of 20.7% for chlorambucil and prednisone combined, 11.8% for hydrocortisone with triiodothyronine, and 9.8% for chlorambucil alone were defined. For the patient with advancing metastatic disease who has received initial hormonal therapy, it is recommended that further treatment with the combination of chlorambucil and prednisone be considered.